Podcasts about Asos

Checkout our Study Courses for free by enrolling below:https://www.wificfi.com/account/studycourses- Private Pilot Study Course- Instrument Rating Study Course- Commercial Pilot Study Course- CFI Study Course- CFII Study Course- Multi Engine Add-On Study CourseCheckout our Checkride Lesson Plans for free by enrolling below:https://www.wificfi.com/account/lessonplans- CFI Lesson Plans- CFII Lesson Plans- MEI Add-On Lesson PlansCheckout our Teaching Courses for free by enrolling below:https://www.wificfi.com/account/teachingcourses- Teach Private Pilot- Teach Instrument Rating- Teach Commercial Pilot- Teach CFI Initial- Teach CFII Add-OnSupport the show

In this week's LuxeGen Group Chat, the girls are diving into everything from celebrity wedding drama to the FIFA World Cup halftime show line-up – and it's chaotic in the best way. From debating Harry and Zoë's guest list situation to seriously considering applying to be Shakira's back-up dancers, this episode has it all.The team also break down ‘Mamma Mia! The Party' at the O2, share their current fashion favourites from Mango, Zara, ASOS and Bershka, and discuss the TV series everyone should be watching if you're missing ‘The Summer I Turned Pretty'.Plus, there's a deep dive into David Beckham officially becoming the UK's first billionaire sportsman, Stormzy producing an Ian Wright biopic, BTS fans potentially taking over the World Cup and why celebrity production companies are becoming the new business power move.Expect pop culture chaos, fashion favourites, football debates, iconic impressions and plenty of group chat energy throughout.Subscribe for new episodes every week.PANELPoppy Edmonds | @poppyedmondss | https://www.instagram.com/poppyedmondss/ Dr Martens Arcadia Loafers | https://go.shopmy.us/p-60692466 Next Bleach Blue Denim Shirt | https://go.shopmy.us/p-60692879 Anna Aitken | @annalouiseaitken | https://www.instagram.com/annalouiseaitken/ H&M Knee High Boots | https://go.shopmy.us/p-60692960 ASOS ARRANGE High Neck Leather Curved Top | https://go.shopmy.us/p-60693316 Lola Lawlor | @lolalawlor | https://www.instagram.com/lolalawlor/?hl=en-gb Mango Asymmetrical Cape (Similar) | https://go.shopmy.us/p-60693472 Adidas Gazelle Indoor Shoes | https://go.shopmy.us/p-60693654 

Get the breakdown of Sedge's frameworks in my free newsletter: https://bit.ly/4tNXDkR Apply to work with me: https://bit.ly/499YncxSedge Beswick is a brand and influencer marketing expert who's worked with Red Bull, Nike, and ASOS - where she built the iconic Insider Program - and scaled her own agency to a £24M valuation.In this episode, she breaks down what actually wins in marketing in 2026 - and why most brands don't have a content problem, they have a structure problem.We get into:- Why brand + performance silos are killing growth- How Adidas reinvented itself post-Yeezy (and why working with Molly-Mae makes sense)- The real reason M&S became “cool” again- The inside culture at Red Bull - and why “ask for forgiveness, not permission” works- The ASOS Insider playbook (and how you'd rebuild it today)Sedge also shares:- The eBay sneaker campaign that drove insane demand (and queues around the block)- Why consistency beats constant experimentation in marketing- The 3 P's of personal brand that drove 75% of her agency leads via LinkedIn- Why TikTok Shop is the biggest opportunity right nowPlus: lessons from building and exiting an agency, mistakes founders make, and how to actually build a brand that converts - not just gets attention.Follow Sedge: Instagram: https://www.instagram.com/sedgebeswick/ LinkedIn: https://uk.linkedin.com/in/sedge-beswick Produced by 7xContent: make your own podcast with us: https://www.7xcontent.com/contact Follow Callum: Instagram: https://www.instagram.com/thecallummc/ LinkedIn: https://www.linkedin.com/in/callummcdonnell/ Timestamps:00:00 Intro + Adidas, Yeezy problem & changing strategy 01:00 Why most brands fail (structure problem) 02:00 Brand vs performance (biggest mistake brands make) 03:00 Adidas reinvention + Molly-Mae strategy 05:00 Building brands beyond the founder (Molly-Mae case) 07:00 Why M&S became cool again 09:00 Emotional storytelling in modern marketing 10:00 Long-form content: opportunity or overrated? 11:00 Red Bull culture + “ask for forgiveness” 12:00 Getting arrested at a festival (Red Bull story) 14:00 What makes Red Bull teams different 16:00 Working with Nike vs Red Bull 19:00 Best campaign: eBay sneakers breakdown 21:00 Building a campaign that actually works 23:00 Why most marketing teams are broken 24:30 The importance of consistency (not chopping & changing) 26:00 ASOS lessons + what actually drives sales 28:00 Biggest mistakes brands make today 30:00 How to pitch ideas internally 32:00 Personal brand: what actually works 33:00 75% of leads from LinkedIn (no big following needed) 34:00 The 3 P's: Perspective, Proof, Personality 36:00 Where to focus today (platform strategy) 37:00 Why TikTok Shop is the biggest opportunity 39:00 Luxury brands + Emma Grede blueprint 42:00 Personal brands doing it right 44:00 Founder vs operator (why most creators get it wrong) 46:00 Finding your “superpower” as a founder 49:00 ASOS insider program deep dive 52:00 How to build a creator program today 54:00 How brands should work with creators long-term 55:00 Scaling & selling an agency (£24M valuation) 57:00 Biggest business lessons & mistakes

En este episodio 480, segunda parte del especial sobre los errores más caros del ecommerce, te traigo los 30 errores cotidianos que están haciendo perder dinero a las tiendas online ahora mismo, en este año. Errores técnicos, errores estratégicos y errores de bulto que muchos dueños de tiendas ni siquiera saben que están cometiendo. Ahora puedes crear y configurar fácilmente tu propia tienda online en solo unas horas sin conocimientos de programación y con todas las funcionalidades incluidas que necesitas para crecer. Haz clic aquí para empezar tus 14 días de prueba gratis sin meter tarjeta de crédito.La semana pasada te conté los grandes desastres del ecommerce, los Amazon Prime Day caídos, los hackeos millonarios y las PlayStations vendidas por error.Hoy bajamos al barro todavía más sobre lo que está pasando hoy en día. Y lo más importante: con datos y algunas soluciones aplicables desde ahora mismo. Comenzamos esta historia en este episodio 480 del podcast de Ecosistema Ecommerce.Por qué una web que tarda 5 segundos convierte 2,5 veces menos que una de 1 segundoEl error de checkout que hace que el 22% de tus clientes se vayan sin pagar.Cómo ASOS aumentó conversiones un 50% con un solo cambio.Por qué retener clientes da hasta un 95% más de beneficio que captarlos.Y muchas otras cosas que te cuento en este podcast, como siempre, sin filtros.Patrocinador del podcast: https://stgrnd.co/esecommerceProyecto X: https://pychon.com/Web: https://ecosistemaecommerce.com/Linkedin: https://www.linkedin.com/in/javierlopezrod/Facebook: https://www.facebook.com/people/Ecosistema-Ecommerce/61550625909016/Twitter: https://twitter.com/ecosistemaecommTik Tok: https://www.tiktok.com/@ecosistemaecommerceInstagram: https://www.instagram.com/ecosistemaecommerce/Youtube: https://www.youtube.com/channel/UCE2zroaDzTVZRwNOh5Ma9cg

Is Robb's new bride a spy? Is Jeyne using Maggy-the-Frog witchcraft on the Young Wolf? Arthur Amalvy discusses the various possibilities. Theme song: ⁠Game of Thrones (80's TV Theme)⁠ by ⁠Highway Superstar⁠ Hey there!  Check out ⁠https://support.baldmove.com/⁠ to find out how you can gain access to ALL of our premium content, as well as ad-free versions of the podcasts! ⁠Join the Club!⁠ Join the discussion:  ⁠book@baldmove.com⁠  | ⁠Discord⁠ | ⁠Reddit ⁠| ⁠Forums⁠ ⁠Leave Us A Review on Apple Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

On this week's episode of the LuxGen Group Chat, the girls are diving into all the latest pop culture chaos, fashion news and internet drama. From Hailey Bieber becoming the new face of Mango to Olivia Neill's ASOS campaign era, the team unpack why high-street brands are leaning into Gen Z ambassadors – and whether celebrity collaborations still have the same impact.They also dig into the latest ‘Euphoria' discourse, including why this season feels completely different and whether the show has lost the magic that made everyone obsessed with it in the first place. Plus, there's plenty of Met Gala chat, including the Chanel look that sparked major debate online.Elsewhere, the group reacts to the wild revelation that celebrity hairstylist Chris Appleton reportedly charged $200,000 for a hair appointment, before unpacking the internet's latest obsession: Emma Chamberlain, her ex-boyfriend drama and the TikTok cover everyone's talking about.Expect hot takes, fashion finds, F1 gossip, Copenhagen shopping recommendations and the brands the team are loving right now. Make sure you're subscribed and let us know your thoughts in the comments.PANELIndia Agyemen | @indiaagy | https://www.instagram.com/indiaagy/We The Free Triple Kick Bomber Jacket | https://go.shopmy.us/p-57655438 Isabel Marant Bekett Suede High-Top Trainers | https://go.shopmy.us/p-57655521 Anna Aitken | @annalouiseaitken  | https://www.instagram.com/annalouiseaitken/ ASOS Charcoal Funnel Neck Jacket | https://go.shopmy.us/p-57655759 ASOS DESIGN Drop Waist Skirt | https://go.shopmy.us/p-57656132 M&S Retro Runner Trainers | https://go.shopmy.us/p-57656198 Lola Lawlor | @lolalawlor | https://www.instagram.com/lolalawlor/ Kangol Tropic 504 Flat Cap | https://go.shopmy.us/p-57656423 Massimo Dutti Transparent Bomber Jacket | https://go.shopmy.us/p-57656537 Pull & Bear Sarouel Trousers (Similar) | https://go.shopmy.us/p-57656662 Mango Spot Print Scarf | https://go.shopmy.us/p-57656737 Lounge Florrie Loafers | https://lounge.com/products/florrie-loafers-chocolate  THINGS WE'RE LOVINGMango Button Embellished Beach Cover Up | https://go.shopmy.us/p-57656985 Boii Studios | https://boiistudios.com/en/Juju Jellies Dani Mule | https://go.shopmy.us/p-57657207 Melissa Thong Kitten Heel | https://go.shopmy.us/p-57658636 Linzi Marine Black Jelly Flip Flops | https://go.shopmy.us/p-57658745 Scandivv V-neck Top | https://go.shopmy.us/p-57658825

In this episode we discuss ASOS, RELX, British Land Co, LSEG, Reckitt & Associated British Foods$asc $rel $blnd $lseg $rkt $abf#asc #rel #blnd #lseg #rkt #abf

Does Arya act with morality in a time of war? What weapon is best in the medieval period? What genre of music did the common folks listen to? Phyllis Jestice joins to discuss. Then HOTD-Ray drops in to explain his fantasy auction debacle. Theme song: Game of Thrones (80's TV Theme) by Highway Superstar Hey there!  Check out https://support.baldmove.com/ to find out how you can gain access to ALL of our premium content, as well as ad-free versions of the podcasts! Join the Club! Join the discussion:  book@baldmove.com  | Discord | Reddit | Forums Leave Us A Review on Apple Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

I came up with at least one way to tell the difference between making a fair profit and profiteering. If someone makes more money when the patients or members they serve are worse off, yeah, call that profiteering. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. For more on what is fair profit versus what is profiteering, I would recommend you go back and listen to the episodes on mission and margin with Ben Schwartz, MD, MBA (EP481) and then with Mick Connors, MD (EP495). But it's probably not an accident that I have started an episode about Medicare Advantage in this fashion. To this end, I am very much looking forward to hearing what's up with Medicare Advantage from the one and only Betsy Seals, who is back for her third appearance on Relentless Health Value. And her advice in a nutshell is this: Don't profiteer. There are ample ways to make a fair profit. Just go back to basics and do it the right way. I wanna kind of tick through the list of things that I think about when I think about Medicare Advantage and just how it is relevant to absolutely everybody. The first thing I think about when I think about Medicare Advantage—and this is very obvious—is what Medicare Advantage plans do or don't do are our tax dollars at work or not at work, as the case may be. Along these same lines, the second thing: How does this impact our elders, our family, our friends, our grandparents? These are our senior citizens, getting the care or not getting the care that they may need. Those two are obvious. Now let's talk about a few less obvious things. Here's the third point that I think about as I listen to conversations about Medicare Advantage: cost shifting. Right? It is a well-known fact how big, vertically integrated carriers—and when I say big, vertically integrated carriers, I mean ones that have a Medicare Advantage line of business—when negotiating with big, consolidated health systems, the release valve of those negotiations is commercial rates. These are the rates that the self-insured employers are paying. So, the carrier says, "Look, gimme the best Medicare Advantage rates. I want the best Medicare Advantage rates because I, the carrier, am paying for those." Savings from those lower rates accrues to the Medicare Advantage plan and its shareholders or investors or executives, right? So, the carrier with the Medicare Advantage plan is like, "Look, go as low as we can go on the Medicare Advantage rates, but it's okay, health system, if you make up the difference with the ASO commercial book of business." Because right … ASO means administrative services only. It's not the carrier who's paying those commercial rates at the end of the day. So, the carrier uses its full book of business to negotiate lower rates for itself while, at the same time, cost shifting to commercial members. In fact, there was some research that was cited. It was episode 436 with Elizabeth Mitchell, and I quoted Luke Prettol. But there was research that puts this markup at 4.7% above what employers would otherwise pay if they had an ASO that did not have a Medicare Advantage Plan. So, yeah … number three big thing that I think about when listening to MA insights like the ones that Betsy drops today, I think about will this accelerate or ameliorate or really have anything to do with what is going on around those negotiating tables with ASOs and health systems? Because let's not forget, health systems account for about 50% of most self-insured employers' total health spend. The fourth thing that I think about: Will MA carriers underpay independent practices, especially primary care practices? Will it pay indies less? And then if it pays 'em a lot less, would ultimately manage to put them out of business, ultimately raising the total cost of care for everybody. But if we're thinking about this strictly from Medicare Advantage financial perspective, a really great move here, these are big, vertically integrated companies, don't forget. Many of them own provider organizations. This is why the FTC tends to frown on vertical integration. So, will these Medicare Advantage organizations who own provider organizations pay the provider organizations they own more? By the way, it's the same thing that's going on on the pharmacy side of the house when a PBM pays pharmacies that they own more. Here's a LinkedIn post by Stanley Warren about this topic. And there are a lot of obvious, maybe less obvious reasons for why paying providers the carrier itself owns more is a great short-term move. One of them is intracompany eliminations. Listen to the episode with Preston Alexander (EP482). But here's another reason: Rate increases paid by the government for Medicare Advantage plans are based on fee-for-service benchmarks. So, if fee-for-service rates go up, then the Medicare Advantage plans can negotiate more money for themselves. If the MA plans own the providers that are charging said FFS rates, then this is, I don't know, a great strategy, especially given the lobbying budget that some of these entities have. So, look … on today's show, I get the distinct opportunity to speak with Betsy Seals, my guest today, as I mentioned earlier; and we go through her advice for MA plans and what they need to get busy with and ensure, make a fair profit, go back to basics, and do it the right way. That's her bottom-line advice. Don't be putting your hands in the cookie jar. Sooner or later, you're gonna get caught. Focus on the members that you're really good at serving. And lastly, when it comes to STARS or other quality measures, lift them the right way—like, actually through better member health and actually better member experience, not some engineered mechanism by which one can check a box that honestly doesn't deserve to get checked. Because now we're back to the beginning and you're gonna get caught with your hand in the cookie jar, and it's profiteering. Let's just get real about that. If somebody's checking boxes that they don't deserve to check, member health is not improving. Betsy Seals, my guest today, as I have said at least three times, co-founded Rebellis Group, which is a Medicare Advantage consultancy. She became CEO of its parent company, Alerion Advisors. Now she is a board member, and also she works with start-ups in our industry. This podcast is sponsored by Aventria Health Group with an assist today from Payerset to help us with the financial support that we need to stay on the air. And with that, here is my conversation with Betsy Seals. Also mentioned in this episode are Alerion Advisors; Rebellis Group; Benjamin Schwartz, MD, MBA; Mick Connors, MD; Elizabeth Mitchell; Luke Prettol; Luke Trocchio; LoVasco; Stanley Warren; Preston Alexander; Aventria Health Group; Payerset; Eric Bricker, MD; Scott Conard, MD; Bob Herman; and Vivian Ho, PhD. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here.   You can learn more by visiting the Rebellis Group blog and by connecting with Betsy on LinkedIn. You can also email her at bseals@rebellisgroup.com.     Betsy Seals is the co-founder of Rebellis Group, former CEO of Rebellis Group and Alerion Advisors, and a current board member of the Alerion Advisors family of companies. With over 25 years of experience across Medicare and Medicaid programs, Betsy is a nationally recognized leader known for her regulatory expertise, strategic vision, and ability to deliver measurable results. Betsy's work spans mergers and acquisitions, compliance, enterprise strategy, sales and marketing, supplemental benefits, and innovative benefit design that optimizes health plan performance and improves health outcomes. Betsy brings a strong blend of executive leadership, business acumen, and deep regulatory knowledge, with a focus on driving operational excellence and meaningful member impact.   00:00 Introduction to this episode. 00:43 Past episodes on profiteering: EP481 with Benjamin Schwartz, MD, MBA, and EP495 with Mick Connors, MD. 01:25 How Medicare Advantage is relevant to everyone. 06:15 A preview of today's conversation. 07:49 The "state of the state" of Medicare Advantage plans. 08:49 Video by Eric Bricker, MD, on the financial performance of the U.S. healthcare system. 09:32 Does Medicare Advantage's losses matter to the patients? 10:29 A recap of Betsy's insights so far. 11:19 The underlying strategic through line that needs to be considered. 13:04 The impact of Goodhart's Law. 14:12 What the players that are succeeding right now are doing. 14:22 The first pillar of a back-to-basics strategy: Don't get caught with your hand in the cookie jar. 16:07 EP463 with Betsy Seals. 16:50 Why short-term strategies don't work. 18:26 Stats report on prior authorizations serving the beneficiary. 19:32 EP482 with Preston Alexander. 19:38 Why prior authorization needs change. 21:28 The better strategy to use. 21:43 EP462 with Scott Conard, MD. 23:17 The second pillar of a back-to-basics strategy: Focus on the beneficiaries you actually serve well. 24:37 What it looks like to implement this focus on the beneficiaries you serve well. 25:29 How special needs plans play into this. 27:43 The third pillar of a back-to-basics strategy: Think about how STARS in clinical programs improve health. 30:04 The ethical component to implementing a Medicare Advantage program. 31:04 Betsy's advice for independent practices dealing with prior authorizations. 33:37 STAT article by Bob Herman about the effectiveness of Medicare Advantage lobbying on policy. 34:08 Betsy's final notes for all players impacted by what's currently happening.   @betsyseals discusses the impact of #medicareadvantage news on our #healthcarepodcast. #healthcare #podcast #financialhealth #commercialpayermarketplace #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Patrick Nelli; Lee Lewis; Stacey Richter with 15 experts (EP507); Jerry DiMaso; Dr Ahilan Sivaganesan; Ryan Jacobs; Stacey Richter (INBW46); Ryan Wells, Dr Leo Spector, and Adam Stavisky  

Antisense-Oligonukleotide (ASOs) sind eine der spannendsten Entwicklungen der modernen Medizin. Diese kurzen künstlichen Nukleotid-Sequenzen können gezielt die Produktion krankheitsverursachender Proteine blockieren oder reparieren. PD Dr. Patrick Weydt erklärt uns, wie ASOs genau funktionieren, wo sie bereits erfolgreich eingesetzt werden und was die größten Herausforderungen sind.

This week on 5 Things Friday UK edition, we break down the retail stories shaping the high street, physical stores, discovery, customer experience, AI, and the future of retail.The episode starts with a spotlight on Positive Retail, described in the conversation as a more curated, “posh TK Maxx” approach to giving unsold fashion stock a second life without leaning into chaotic discount culture. The discussion then moves to Longchamp's Sloane Square pop-up, a beach-club-style activation built around music, drinks, games, workshops, and summer holiday energy — a strong example of why physical retail has to offer something the internet cannot.The conversation also covers the reported return of Claire's to UK high streets, with plans mentioned in the episode for 50 stores, before moving into takeaways from World Retail Congress in Berlin. Topics include CEO perspectives on AI, customer experience, retail engagement, ASOS collaborations, the role of Reddit in AI training, and whether retailers should be paying closer attention to Reddit and community-driven search behaviour.The episode wraps with store visits and retail models from Europe, including Action's frugal operating model, the question of whether AI removes organisational “fluff,” and examples from OBI, QVC live shopping, NRF Europe, and HOFF's Madrid flagship store.Linkshttps://positive-retail.com/https://www.nrfbigshoweurope.com/en/about/event-overviewhttps://www.instagram.com/reels/DXuOaYxggjU/Chapters00:00 Introduction to 5 Things Friday UK00:27 Meet Simone and Need It For Tonight01:15 Positive Retail and a different future for fashion02:12 Overproduction, discounting, and retail's race to the bottom02:36 The “posh TK Maxx” model of curated discovery03:49 Longchamp's Sloane Square beach-club pop-up04:26 Why physical retail needs emotion and atmosphere05:21 Claire's planned return to UK high streets06:06 World Retail Congress in Berlin06:32 CEOs on AI, customer experience, and retail engagement06:51 ASOS, collaborations, and sell-out retail moments07:13 Reddit, AI training, and retail discovery08:33 Who actually uses Reddit?09:45 Inside Action's frugal European retail model10:33 Centralised operations, SKUs, and efficiency11:00 Is AI just removing organisational fluff?11:24 Action opening one store a day11:52 OBI, garden retail, and store experience12:13 QVC and the move into live shopping12:37 NRF Europe, London, Milan, Amsterdam, and Paris13:24 HOFF's Madrid flagship store13:49 Pulse, London plans, and new social content14:14 Closing remarks

Is Varys part of the Grand Maester Conspiracy? Did Shae ever love Tyrion? Pádraig MacCarron joins to discuss. Theme song: Game of Thrones (80's TV Theme) by Highway Superstar Hey there!  Check out https://support.baldmove.com/ to find out how you can gain access to ALL of our premium content, as well as ad-free versions of the podcasts! Join the Club! Join the discussion:  book@baldmove.com  | Discord | Reddit | Forums Leave Us A Review on Apple Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

Recorded live at the Retail Technology Show at ExCeL London in partnership with TNS. Host Graham Barrett speaks with leaders from across retail, hospitality and technology to explore the pressures shaping store operations, payments, fulfilment and customer experience in 2026. 1/ Jon Cole, Director of Product and Technical Solutions, TNS 2/ Shazmeen Malik, Partner Brands and Flexible Fulfilment Director, ASOS 3/ Martin Ward, Head of Software UK&I, Toshiba 4/ Gemma Edlin, Retail Director, Company Shop Group 5/ Richard Lewis, Group Chief Executive Officer, RedCat Hospitality 6/ Meriel Neighbour, Director of Technology Delivery and Transformation, River Island The episode opens with Jon Cole, Director of Product and Technical Solutions at TNS, who discusses the surge in retailer focus on resilience and cybersecurity and why hybrid cloud/on‑premise architectures are becoming essential. Next, Shazmeen Malik, Partner Brands & Flexible Fulfilment Director at ASOS, dives into the art of marketplace curation. She explains how ASOS balances global brands with emerging labels, why 20% of its branded portfolio is now newly onboarded, and how flexible fulfilment models, from partner fulfilment to ASOS Fulfilment Services, enable scale without compromising customer experience. Shazmeen also shares how ASOS is using AI for personalisation, outfitting and virtual try‑on, describing it as “super exciting” for discovery‑led shopping. We then hear from Martin Ward, Head of Software UK&I at Toshiba, who explores why retail transformations fail when they prioritise technology over people. He reflects on Toshiba's work with Matalan, the importance of involving store colleagues early, and why retailers must “test and learn and fail fast” to drive meaningful change. Martin also offers a grounded view on Agentic AI, its potential, its risks, and why adoption must be purposeful rather than hype‑driven. Next, Gemma Edlin, newly appointed Retail Director at Company Shop Group, explains how the UK's largest surplus supermarket prevents waste at scale, redistributing products from over 800 brands and stopping 47,000 tonnes of waste last year alone. She discusses dynamic pricing, robotics in the warehouse, and how AI could help set “the right price first time” to balance commercial viability with affordability and trust. Richard Lewis, Group CEO of RedCat Hospitality, shares a hospitality perspective on loyalty and digital micro‑donations. He emphasises that loyalty begins with consistently great experiences: “customers don't give you praise for getting the basics right, but when you get it wrong, they tell you”. He explores how data, communication and digital engagement can drive frequency across pubs and hotels. Finally, Meriel Neighbour, Director of Technology Delivery and Transformation, River Island closes the episode with a fashion retail perspective, sharing how a major high‑street brand is thinking about modern store operations, digital enablement and the evolving role of the physical store in a technology‑rich, customer‑driven world. A rich, fast‑paced episode capturing the realities of modern retail and hospitality, from cybersecurity and payments infrastructure to marketplace strategy, store transformation, waste reduction and customer loyalty.

Retail is moving fast, and this week's Five Things Friday breaks down the brand moves that matter.Alex is joined by Simone, co-founder and CEO of NIFT — Need It For Tonight, a rapid delivery infrastructure business powering retail through a fashion marketplace app and B2B plugin.This episode covers Louis Vuitton's immersive Mayfair “hotel” pop-up, why luxury brands are leaning into experience-led marketing, how brands are activating around the London Marathon, Clarks' move into marketplace retail, ASOS' latest results, and the growing cost pressures facing UK retailers.The key theme: brands can no longer just show up. They need to become part of the moment.In this episode:Louis Vuitton's Mayfair pop-up experience and why it is a marketing moment, not just a retail momentThe shift from traditional event sponsorship to brands becoming part of the eventLondon Marathon activations from brands including Vaseline, New Balance, Wintergreen Sport and AppleClarks' move beyond footwear into an online marketplace with brands including Adidas, Nike, Tommy Hilfiger and Hugo BossWhat Clarks can learn from Next's multi-brand platform strategyASOS' mixed results, improved adjusted EBITDA and narrowing lossesWhy Middle East conflict, supply chain pressure and rising costs remain critical concerns for retailFeaturing:SimoneCo-founder and CEO, NIFT — Need It For TonightWatch for a sharp breakdown of where retail, fashion, luxury and event marketing are heading next.Chapters00:00 Introduction and welcome to Five Things Friday00:35 Meet Simone, co-founder and CEO of NIFT — Need It For Tonight01:25 Louis Vuitton's new Mayfair “hotel” pop-up experience02:20 Immersive luxury retail and theatrical brand activations03:18 Why the Louis Vuitton pop-up is a marketing moment03:46 Luxury slowdown, FOMO and the need to repair the customer relationship04:10 London Marathon week and event-led retail marketing05:06 Marathon brand activations from Wintergreen Sport, Apple and others05:55 Why brands need to become part of the event06:25 Clarks launches its first online marketplace07:04 Why Clarks is expanding beyond shoes07:22 Marketplace retail strategy and the Next comparison08:21 ASOS results, revenue and adjusted EBITDA growth09:14 UK GMV growth and retail cost pressures10:11 Why retailers may need to prepare for a difficult winter10:41 Rising retail costs and how brands can respond11:02 Logistics, delivery and final thoughts with Simone

Stephanie Barbe Hammer drops in to discuss Jaime's arrested development. Check out her new book: The Warbler School Chronicles.  Theme song: Game of Thrones (80's TV Theme) by Highway Superstar Hey there!  Check out https://support.baldmove.com/ to find out how you can gain access to ALL of our premium content, as well as ad-free versions of the podcasts! Join the Club! Join the discussion:  book@baldmove.com  | Discord | Reddit | Forums Leave Us A Review on Apple Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

How do you run a global fashion marketplace serving 18 million active customers across 200 markets while keeping assortment fresh, fulfillment fast, and brand partnerships strong? Live from Retail Technology Show 2026 in London, Chris Walton sits down with Shazmeen Malik, Partner Brands and Flexible Fulfillment Director at ASOS, to discuss how ASOS is evolving its marketplace model through smarter fulfillment, curated brand growth, and AI-powered merchandising. Shazmeen explains how ASOS balances wholesale, partner-fulfilled, and ASOS Fulfillment Services models to better serve customers and brand partners around the world. Key Topics Covered: • How ASOS manages a global marketplace across 200 markets • The three fulfillment models powering partner brand growth • Why flexible fulfillment improves speed, localization, and choice • How ASOS decides the right model for each brand partner • Using fulfillment to localize assortments by market and region • Why multi-brand retail is different from single-brand retail • How AI will reshape buying and merchandising teams • Why AI gives merchants more time for creativity and strategy • How AI can improve product discovery and outfit building Thank you to Vusion for supporting our coverage from Retail Technology Show 2026. #RetailTechnologyShow #ASOS #FashionRetail #Marketplace #RetailInnovation #SupplyChain #OmniTalkRetail

In this episode we discuss Unilever, AG Barr, Boohoo, Wise, ASOS & Netflix$ulvr $bag $debs $wise $asc $nflx#ulvr #bag #debs #wise #asc #nflx

Phil Haberkern (Boston University) talks about fire magic, Edric Storm, and the Saan-Seaworth bromance. Theme song: Game of Thrones (80's TV Theme) by Highway Superstar Hey there!  Check out https://support.baldmove.com/ to find out how you can gain access to ALL of our premium content, as well as ad-free versions of the podcasts! Join the Club! Join the discussion:  book@baldmove.com  | Discord | Reddit | Forums Leave Us A Review on Apple Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

Physical retail isn't dead, boring retail is.This episode breaks down the smart retail moves winning right now: collabs, pop-ups, experiences, and loyalty that works across ecosystems.In this episode of Five Things Friday, the conversation covers the retail stories shaping the week — from Adidas and ASOS taking their collaboration into physical retail, to the continued rise of experience-led stores, regional expansion, pop-up strategy, and loyalty programs becoming more flexible and currency-like.The episode opens with Simon, co-founder and CEO of Need It For Tonight, who explains how the business powers instant retail delivery through both a marketplace app and a rapid delivery checkout plugin for retailers.From there, the discussion moves through five standout themes:Adidas x ASOS expanding womenswear collaboration into physical retailWhy more brands are borrowing each other's channels instead of owning everything themselvesWhy physical retail still works when the experience is strongNew store and pop-up concepts from Boots, FatFace, and RefyWhy Nectar points being used on Uber and Uber Eats could signal a major shift in loyalty strategyThis episode is a sharp snapshot of what modern retail looks like right now: more collaborative, more experiential, more local, and more integrated into everyday customer behavior.Chapter timestamps00:00 Intro and rough start to Five Things Friday00:17 Guest intro: Simon from Need It For Tonight00:32 What Need It For Tonight does: instant delivery infrastructure for retail00:51 Adidas and ASOS expand their womenswear collaboration01:15 Why physical retail matters for a digital-first brand like ASOS01:36 Brands borrowing each other's channels instead of owning everything02:18 Bigger baskets: full looks, accessories, and considered audience strategy02:46 Why physical retail is performing when experience is strong03:42 The rise of third spaces and brands expanding beyond London03:50 Boots launches a more premium opticians concept04:08 Different ways brands are selling the same category through experience04:52 FatFace expansion in regional locations05:23 Refy's Soho pop-up and turning customer service into an experience06:13 Nectar points can now be used on Uber and Uber Eats06:44 Why loyalty is starting to behave more like currency07:29 Why this is smart for both Sainsbury's and Uber08:08 What's coming next week and closing thoughts#Retail #Ecommerce #RetailStrategy #Loyalty #PhysicalRetail #BrandCollabs #ExperientialRetail

Aron offers news of a Game of Thrones film. Then Padraig, Hazel and Elysia discuss Bran's choice to trek beyond the Wall. Also, does Hodor have a magic sword? Theme song: Game of Thrones (80's TV Theme) by Highway Superstar Hey there!  Check out https://support.baldmove.com/ to find out how you can gain access to ALL of our premium content, as well as ad-free versions of the podcasts! Join the Club! Join the discussion:  book@baldmove.com  | Discord | Reddit | Forums Leave Us A Review on Apple Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

What do King Charles III, David Beckham, Paul McCartney, Emma Watson, Gwyneth Paltrow, Jamie Laing and Stacey Dooley have in common with The Happier Life Project host Gabby Sanderson? The answer is the theme of today's episode: homeopathy. Homeopathy is an alternative approach to wellbeing that considers the whole person; emotional, mental, and physical, rather than focusing solely on symptoms. It's based on the idea that the body has an innate ability to rebalance itself, and that highly diluted natural substances may help stimulate that process.  Gabby brings this conversation to the podcast following her own profoundly positive personal experience. Over recent months, she has noticed significant shifts in her mental and emotional wellbeing while working with homeopathy. Aware that the topic can spark both curiosity and scepticism, she invites listeners to stay open, to listen with curiosity rather than conclusions, especially if the practice is new or unfamiliar. Gabby is joined by two guests with deep expertise and lived experience in the field. Helen Johnson is an osteopath, naturopath, cranial osteopath, and homeopath with decades of experience in holistic medicine. She now leads professional training programmes, including The River School of Homeopathy, where students qualify to practise as homeopaths. Alongside her is Katrina “Trina” McLaren, who transitioned from a successful global marketing career — including over six years at ASOS — into the world of healing. After training in Reiki Levels I and II, Trina went on to study homeopathy under Helen and now practises professionally. She is also Gabby's personal homeopath. In this episode, Gabby, Helen, and Trina explore what homeopathy is, how it works, who it may support, and what the healing process can feel like, particularly in relation to emotional and mental wellbeing. They also discuss the history of homeopathy, its widespread use in India, and its growing resurgence in the Western world. Helen and Trina share real-life examples from their work, offering insight into how homeopathy has been used to support individuals through deep emotional challenges. For Gabby, hearing these stories, alongside her own experience, has opened her eyes to the potential depth of this approach. If you're curious about alternative pathways to healing, or simply open to exploring different perspectives on wellbeing, this episode invites you into a thoughtful and nuanced conversation. To download the free My Possible Self App: https://mypossibleself.app.link/podcast To follow My Possible Self on Instagram: https://www.instagram.com/mypossibleself/ Helen Johnson website: https://www.helenjohnson.org/ Katrina McLaren website: www.katrinamclaren.com River School of Homeopathy: https://www.riverschoolofhomeopathy.org/who-we-are/ River School of Homeopathy Instagram: https://www.instagram.com/riverschoolofhomeopathy/ For more information on research into homeopathic medicine, visit the Homeopathic Research Institute: https://www.hri-research.org/resources/homeopathy-faqs/ The short YouTube video Helen refers to when discussing the memory of water: https://www.youtube.com/watch?v=MZmYcJ0DNBc The longer YouTube video Helen refers to when discussing the memory of water: https://www.youtube.com/watch?v=R8VyUsVOic0    

In this episode, Victoria sits down with Hannah Krohne, Hannah Lizzy on TikTok, a fashion creator who turned TikTok into a launching point for her career. Landing roles at David Yurman, Danielle and Alix in styling, and ASOS in merchandising and trend analysis before ultimately going full-time as an influencer. They discuss her path from posting in her college dorm to building a platform that now functions as both content and portfolio. Hannah shares what it really looks like to balance a 9–5 with content creation, from filming multiple videos a day to navigating the transition out of corporate. They also get into the financial realities of influencing, including inconsistent income, brand deals, and the unexpected costs behind “free” product.The conversation breaks down how brands actually choose influencers, the behind-the-scenes of Fashion Week dressing, and why so much of what you see online isn't as it seems. They also explore the role of content in building a career in fashion, why you don't need a traditional fashion background, and how to position yourself for opportunities in the industry.Follow Fashion & Founders:Podcast IG: @fashionandfoundersPodcast Substack: Fashion and FoundersPodcast Website: fashionandfounders.comPodcast TikTok: @fashionandfoundersPodcast LinkedIn: Fashion and FoundersPodcast YouTube: Fashion and FoundersPodcast Links: Shop MyFollow Hannah:IG: @hannahlizzy_TikTok: @hannahlizzy_Brand Highlight: Paris64Glamsquad:Code: FASHIONANDFOUNDERS for $20 offRent the Runway:Use code: RTRXVSMITH50 and get 50% off your first month!Thanks for listening! 

David Peterson discusses translation for Knight of the Seven Kingdoms and reveals the misunderstood origin of the word "Dracarys." Then Melanie, Ray, and Nolan discuss the book-only plot twist that lands Dany in Meereen forever. Theme song: Game of Thrones (80's TV Theme) by Highway Superstar Hey there!  Check out https://support.baldmove.com/ to find out how you can gain access to ALL of our premium content, as well as ad-free versions of the podcasts! Join the Club! Join the discussion:  book@baldmove.com  | Discord | Reddit | Forums Leave Us A Review on Apple Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

The girls have been everywhere this week. Ashley's been deep in the chaos of organising a photoshoot for her brand-new product line, while Lauren's been living her best life in London, hitting an ASOS fashion event and even stepping into the guest seat on a podcast.The “Witchy Woo” saga continues… and this time it's James' turn. Lauren's fella has his first psychic experience and let's just say, the results were not what anyone expected. Safe to say, he's now fully converted.Elsewhere, the girls vent about one of their biggest icks: loud men (you know the type), and share their top purchase picks of the week that you need to know about.And remember “fleece girl”? The mysterious night she couldn't quite piece together? Well… we've got an update.Head over to our socials @niptuckpod and click the link in our bio to find our YouTube, where full video episodes will be released every Wednesday at 5pm. If you're a Patreon member, not only will you get the Wednesday main episode the day before at 5pm, you'll now be able to watch the Friday Bonus too!Get in touch with your questions, dilemmas and Slutty Susie's via our Whatsapp or email hello@niptuckpod.com

"Blue Horseshoe loves Anacott Steel." Today we cover recent clinical trial news in the FSHD space and delve a bit deeper into some topics from part 1 of our Reddit Q&A. **Updated version**The lowlight was Roche canceling their trial. The highlight was Sarepta's announcement of preliminary clinical data. Getting siRNAs, ASOs, and viruses into liver is easy because liver is filled with leaky capillaries, however, muscle is poorly vascularized and blood vessels have tight junctions so targeting cell receptors for enhanced transcytosis greatly enhances skeletal muscle delivery. Sarepta's targeting of the alpha v beta 6 integrin is a great advance in delivery of siRNA against DUX4 and, as predicted, shows the best DUX4 knockdown we have seen so far.

A.Ron and Anthony dive deep into Westerosi spycraft, mythology, songs, and the introduction to Tormund Giantsbane. Theme song: Game of Thrones (80's TV Theme) by Highway Superstar Hey there!  Check out https://support.baldmove.com/ to find out how you can gain access to ALL of our premium content, as well as ad-free versions of the podcasts! Join the Club! Join the discussion:  book@baldmove.com  | Discord | Reddit | Forums Leave Us A Review on Apple Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we explore how individualised medicines are evolving from “n=1” treatments (a treatment effective for a single individual) into approaches that could transform care for many people living with rare conditions.  Advances in genomic medicine are making it possible to design highly targeted treatments based on an individual's genetic information. While these therapies may begin as bespoke solutions for a single patient, they can often be adapted, refined or reused to benefit others with similar conditions.  While the research is evolving, the systems needed to deliver these treatments at scale are still catching up. From regulation to access, our guests discuss what needs to change to turn this potential into reality.  Our host Sharon Jones, is joined by:  Ana Lisa Tavares, Clinical Lead for Rare Disease Research at Genomics England  Mel Dixon, Participant Panel member and CEO and Founder of Cure DHDDS  If you enjoyed today's conversation, please like and share wherever you listen to your podcasts.  “However rare your condition is, someone has a right to have hope. Everybody should have a hope that we should be able to find a treatment.” You can download the transcript or read it below. Sharon: What if treatments once designed for just one person could now help many others? Thanks to advances in genomic medicine, regulations are changing and research is expanding. This opens up more options for treatments for rare conditions. But what does this mean and how close is real change? I'm Sharon Jones, and this is Behind the Genes. We look at how genomics is changing healthcare, covering everything from cutting-edge research to real-life stories. Individualised medicines are a fast-moving area, but there's still a big gap between scientific progress and what's actually happening to patients. You could call it the gap between hype and hope. Ana Lisa: However rare your condition is, someone has a right to have hope. Everybody should have a hope that we should be able to find a treatment. Sharon: Coming up, we'll hear from Ana Lisa Tavares, Clinical Lead for Rare Disease Research at Genomics England, and Consultant in Clinical Genetics at Cambridge University Hospital, as well as Mel Dixon, member of the Participant Panel at Genomics England and CEO and founder of Cure DHDDS. Mel opens this chat by explaining why developments in individualised healthcare really matter to her. Mel: This issue is really personal to me. I have three children, two of whom are affected with an ultra-rare DHDDS gene variant, for which there is currently no treatment. Their condition causes symptoms such as, well, it varies between mild to severe learning difficulties, seizures, tremors, and movement and coordination difficulties. But the, the most worrying thing for us was that this condition is actually also progressive. So over time it becomes more of a Parkinsonism and some patients experience dementia-like symptoms and psychosis. So for us to get a treatment that targets the genetic cause of, of their condition is, like, the most important thing in, in our lives. If we could intervene now, they could potentially, at the stage they're at, you know, live an independent life with, with some supports. But if the disease is left to progress, it would be a very different outcome for them. Sharon: I mean, that sounds so difficult and I can't even imagine how life is for you and your family. And I can see what is driving you to find anything to extend the life of your children and to give them that opportunity to, to have a better quality of life. And then Lisa. Ana Lisa: It's a huge burden for families to carry. And I think at the moment there's an additional layer of burden, which shouldn't fall on families, to feel like they need to forge a pathway for their child to have a chance of a treatment. That's, that's a lot to bear. Mel: I think as well, families feel they almost have to become mini scientists in their children's specific condition overnight, because you go to these appointments with the consultants and nobody's heard of the condition and they don't know, they just don't really know what to do with you. So they're asking you, you know, so tell me about this, this gene change. What, what does it do? What does it mean? So you have to become the mini professor in your child's condition to be able to advocate for them. We've had to really learn on our feet so that we're able to advocate and push for research into DHDDS, because without us doing it, nobody else was going to be. Sharon: Yeah. So that's, you know, that's partly what we're here and what this podcast is for, it's here to support families to, to understand this stuff. And Ana Lisa, can you just break it down to us, what is individualised medicines? Ana Lisa: An individualised medicine that's made for one individual person. In reality, sometimes there are other individuals that can also benefit from the same medicines, and sometimes actually, although the medicine is made for one specific person, it might be made using a strategy that other patients could also benefit from, either directly, exactly the same, even, or through tweaking them so that they could work for a different patient. In the context that they're most often referred to at the moment, they're therapies that are being made based on the genetic information about somebody. Sharon: Thank you. I mean, that sounds amazing. And now coming to you, Mel, what does receiving a diagnosis mean for a family? And how do you navigate the space between finally having answers and the reality that the treatment may not yet exist? Mel: So for us, I think, we went down the, the diagnostic route in the hope that we would be able to find a treatment for our children, or there would already be a treatment in place. But unfortunately when we got their diagnosis, we were told that their, their condition was ultra rare, neurodegenerative and also newly discovered. So there was, there was no treatment pathway and actually minimal research happening into it at the time. So it was frustrating, upsetting, um, and it felt like quite a hopeless situation at the start, but actually this was just over three years ago. And through a lot of proactiveness on our part in fundraising, we've been able to better understand the condition and we now have treatments in the pipeline. So in that three-year window, from there being nothing, we now have treatments both in terms of potential drug repurposing candidates and also, um, an individualised therapy called an ASO is also in development for them. So it was hard, but it's given huge benefit to us. Otherwise, we'd just be going, remaining going from specialist to specialist without having any answers or understanding why their symptoms were progressing. Sharon: I mean, that sounds really, really tough and you know, coming back to you, Ana Lisa, could you talk us through how genomics is changing the way we can treat rare conditions? You know, what types of individualised medicines now exist and how do they even work? Ana Lisa: Maybe I'll start with how some of these medicines are working. So with, without going into details, but the sort of principle that these medicines might be able to, to do something called gene editing. So our, our DNA, uh, the instruction manual is made up of genes and it's now can be possible scientifically to change even a single DNA letter code in somebody to try and ameliorate the symptoms of their rare condition. You know that's phenomenal scientific progress to be able to do that. I think a lot of people have heard about gene therapy, where one is trying to get into the body a gene or part of a gene that might be able to sort of replace the function of a gene that isn't working as it should. There are various other strategies. So our DNA is actually used to send messages to our body, if you like, to, to decode these instructions. And so there are medicines that target the next step in this process, the RNA, which are the ASO therapies that Mel was referring to earlier. And really what those are doing are either trying to correct for a protein in our body that isn't working as it should, or to try and get rid of one that shouldn't be there. And so they can act in different ways. And that's actually quite powerful, because you can, theoretically, use these strategies to correct for different genetic rare conditions. So I think going to the sort of first part of your question, maybe if I can phrase it as "directly at source". If you can go upstream and target in a very direct way the cause of a rare condition, then actually you might be able to apply those same principles to many different types of rare condition. We know that there are, you know, 8,000 as a very ballpark number of rare conditions, and it might be that these strategies could be used I don't want to say for all rare conditions, but for many rare conditions where we find the genetic cause, these strategies could collectively be a very powerful way to treat them. And traditionally we've had to understand all the underlying biology, find a druggable target, find a drug that could target that, that's safe, effective, et cetera. And that's a lot of work. And that's still very, very valuable. If we were going to do this for these thousands of conditions, it would probably take us hundreds to thousands of years, collectively. And these strategies provide a lot of hope for being able to do this in a, in a more efficient way, where we can actually use the information used to treat one rare condition and apply those learnings to another rare condition. Sharon : I mean, that's really helpful to understand. So if the science is there, why aren't more patients benefiting from it yet? You know, what's standing in the way from your perspective? Ana Lisa: That's a really good question, and it's complex because the, our whole ecosystem is made up of, of many parts that go from finding a potential strategy that could help a rare condition to a patient benefiting from that. And I think one thing that maybe we haven't touched on yet is the fact that rare conditions can be really rare and affect a really small number of people individually, even though we know collectively they affect so many. You know, in the past it's been easier, if you're taking a condition that's common, that affects thousands of people, it's easier to see and to be sure whether your new medicine is actually working as you think it does and should, and having the benefits that you think. The, the sort of regulators have really clear guidance. We have lots of knowledge about how to assess treatments and have a randomised clinical trial, for example. How the reimbursement process may work in a public healthcare system. And when you, when you, when you sort of set down into the really rare, this is difficult for each stage of the journey. The transformation that's needed is a whole, system-wide transformation to be able to regulate in a scalable, equitable way, these therapies that could actually be an N of one treatment for one individual, that actually maybe one day another individual may also benefit, and sometimes even a group of individuals. It's not just the, the regulator, it's also how do you make it viable. So again, you have to make it scalable, equitable. And even to implement in the NHS down to this very "N equals one" level, and demonstrate that patients could benefit from these treatments, might require sort of fancier ways of assessing these treatments, whether it's statistics, other methodology and I think it's really the system-wide nature that makes this tricky, but is also a fantastic opportunity for, for collaboration, because that, that sort of end goal and benefits could be so, so great. Sharon: Yeah, absolutely. And I mean, Mel, for your side of things, it must sound, you know, quite frustrating where the people in the rare community to not see the support being made more readily available? Mel: Yeah, it is particularly difficult for patients and their families. I think in our case, when you're dealing with a neurodegenerative condition, time is of the essence. So when you know that the science is available or it's ready, but you don't have the systems in place to implement them to the patients so that they can access these much-needed therapies, it's worrying and frustrating. And also I see our children are affected with, with, you know, one of these N of few conditions that there's, you know, there's only 59 confirmed cases of DHDDS worldwide, and we've seen how the system firsthand doesn't fit ultra-rare patients. We can't, when we were looking at drug repurposing, we can't do a traditional clinical trial because we don't have the patient numbers and we don't have the funding. So a placebo-controlled trial just wouldn't be possible for us when there's only, I think, seven confirmed patients in the UK and, um, four that we're actually in, in, in touch with. So it does feel, I think, as Ana Lisa was saying, that we really need a system rethink, um, and refit so that it does start to accommodate these ultra-rare conditions, especially now as there's therapies which are showing huge benefit to patients. Sharon: And so with like all of these challenges, where are you seeing things shift and what does meaningful progress really look like for you? Mel: At the end of last year, the MHRA announced that they were rewriting the regulatory framework for rare conditions, and that fills us with lots of hope for the future. They're recognising that the traditional systems don't work for particularly ultra-rare conditions, and now that we do have these therapies in the pipeline, we, we want to get the patients to be able to access them. And we're also seeing innovation in how evidence is generated and measured. We witnessed this firsthand with our son as he was undergoing baseline tests for his ASO therapy. You know, the use of digital biomarkers, of real-world evidence, how they're increasingly being used for these N of one or N of few populations. And how the individual receiving the treatment becomes their own comparator. So you're not relying on these big natural history studies of the disease or placebo controls. It's you're looking specifically at that individual, getting a really strong baseline and then looking, once they're dosed with the medication, is that improving or stabilising symptoms? So I think this shift in focus is really meaningful for the ultra-rare community and also for them to be part of the decision-making process of what, what benefits do they want from a drug? Like what is meaningful to them? I think there's much more talk about the patients and how the, what will benefit them most. It's not necessarily what the scientists would think or research would think would most benefit, but what, what would make a meaningful difference to the patient? Sharon: I mean, that's good to know because it's kind of putting the person at the centre of, you know, this is what it's all about, isn't it? It's not just the science. We're trying to treat people and it's putting people, people first. Ana Lisa: Just to build on that, it's exactly that, that awareness that is, is growing, I think, that there are so many people affected by a rare condition and, and however rare your condition is, someone has a right to have hope and that the system should be able to cater for many rare conditions, you know, whether they're an ultra-rare or an actually almost common rare condition, everybody should have a hope that we should be able to find a treatment. And it's not a hopeless situation that it's, you know, never going to happen or be too difficult. It's quite powerful, hope. If you can solve for the truly individualised medicine, then you at the same time may also be helping everyone in-between a really common condition and a really rare condition, because right now the system works for common conditions. And if you can take it right down to the sort of radical of, example of an individualised medicine made for one person, then you are also forcing the system to a change for everybody else. And I think that's one of the great benefits of thinking about it as a joined-up system. Sharon: So how do you each navigate between hype versus hope when it comes to rare therapies? Mel? Mel: I like to focus on hope, because when we got our diagnosis, we felt really hopeless and that's a really dark place for a family to be. But as we learnt more about their condition and the rare condition landscape and genomics, we actually learned of all these new therapies that were in the pipeline. We were hearing about, you know, recently, conditions like Huntington's Disease that you never, never previously had any disease-modifying treatment, how they're now being able to be treated with gene therapy with really positive effects. Similarly for other neurodegenerative conditions that have been treated with ASOs, how they're seeing not just disease stabilisation, but improvements. So I know it's, it's still, like, relatively early days with these technologies and therapies, but I think it, it allows families to have hope, which is, which is really, really important, because that statistic, you know, of the, of 95% of rare conditions not having a treatment, it's, it's a really brutal one, uh, to be told at the outset or to learn at the outset. So, you know, if, if these therapies can, can make a huge dent in that, that would be life-changing. It would make a profound difference to many, many families, and I think there's a lot of reason to have hope, taking all of that into consideration. Sharon: And then Lisa? Ana Lisa: I think to work in this area, one needs to be full of hope and optimism because there are so many, um, challenges to overcome as a community. Uh, but I think that means that people are also incredibly collaborative, because they know that we need to work together for this to succeed. And no one, you know, one individual, one organisation can do it on their own. It truly has to be a crosscutting, collaborative endeavour. The fact that we, in the UK, have resources like the National Healthcare System,Genomics England in partnership with the NHS runs a National Genomic Research Library. And so the fact that you could look at, at tens of thousands of, of genomes for many, many individuals with rare conditions. That gives me hope because it means that if a treatment is made for another person, it could be in a different country in the world, and if we could find another patient, it doesn't matter what specialty they're under, where they are, we should be able to find them and connect with their clinical team if, you know, if they've consented for the National Genomic Research Library. And so to me, that feels, that whilst there's, there is a lot of hype in the sense that some of the really well-publicised cases, really had a lot of people working on them and a lot of resources to make it happen. But that gives hope to everybody else that follows that actually it is doable and if we can make better systems, and having these national resources that we do, the fact that, there are a lot of guidelines being written at the moment, both international and national. And again, they show that the sort of scaffolding is starting to be in place to apply these in an equitable scalable way. It might not be that you're so much looking for a specific rare condition as for a particular type of genetic variant that could be targeted in the same strategic way, and that therefore you could look across many different rare conditions. So again, all these sort of pieces of the puzzle are, are filling me with, with, with hope. Sharon: You touched upon, um, inequity there. Now, you know, is there a risk of inequity given what we've talked about in terms of those challenges? Ana Lisa: I think we, we always have to have the lens of equity in everything we, we do. And that, and that really does apply to healthcare and, and in fact, probably the whole rare disease community are, are, are not well served in terms of therapies at the moment. There are so few, um, therapeutic options and so I think there's a massive inequity in that this, our systems are not geared, uh, towards rare conditions. I suppose, you know, different countries have different healthcare systems and some of the sort of first personalised therapies may require a lot of money behind them to, to happen, but they will be pioneers in leading the way for how this can be done. And I think in the UK we have a lot of the infrastructure and the, a sort of a strong, that's very equitable, I think. And so we could do this in a, in a much more open and equitable way. Sharon: Mel? Mel: Cost is always, unfortunately, and it, when it's your family that's affected you, you know, you hate the thought that things are coming down to cost and, and money. But I, I think as Ana Lisa said, if, if the system absorbs the initial cost. You know, it seems that those longer-term costs could come down significantly. We already see with our very small DHDDS community that an ASO, which is an allele specific that was made personally for one, for one child, can actually also benefit my son, even though they have a different variant. So if the cost of the ASO is 1.2 million per person, but if you suddenly find actually one other person can share that, that's almost halving the, the cost. And then if then you're finding out that actually, oh no, 3, 4, 5, 10 people can all have that same ASO, suddenly it becomes much more cost-effective and more sustainable. So I think, as we have to think about cost, I think that also allows us to have more hope that these therapies can, the cost of these therapies that are obviously hugely expensive at the moment, can be brought down in the longer term. Ana Lisa: There are a lot of things that people want to do in the NHS. People can be working under quite hard circumstances, so to talk about making a therapy for one individual can be difficult and people can sometimes, I think, think that it's a pie-in-the-sky conversation. However, I think that, you know, all the clinicians I know who work with families with rare conditions, what they'd most like to be able to do is to be able to offer a therapy. And so I think a lot of people see this as a, as a big opportunity, despite these initial hurdles. One thing I often think about is my grandfather, when he was alive, every phone conversation, he would start with, "How many lives have you saved today?" And so I think that's the, that's our challenge. Sharon: Wow. That's, that's really powerful. Mel: Just echoing really what Ana Lisa was saying, I feel the, um, inequity lies in rare conditions as a, as a whole, from the point of diagnosis to the lack of pathway, um, to, to the lack of system in place for them. You wouldn't have a patient with a life-changing cancer diagnosis receive that information in a telephone call, and that is the stark reality for many rare disease patients. That's how they receive the, that's how they often receive the news. That was certainly our, our experience. And, and from that point, there was then no pathway. It's just this horrendous feeling of isolation. And I think now that there are these treatments in place and therapies in, in place, it's about time we change that because often the rare, the rare condition community, and certainly those with ultra-rare conditions as well, they're probably like some of the most underserved members of the community in that it's their parents and their families that have to advocate. Otherwise, without that, they, they often wouldn't stand a chance of understanding the disease, let alone finding a treatment. So I think the whole system needs to have a reset, to think about these rare condition patients and, put them at the heart as they do for more common conditions. Ana Lisa : I completely agree. And you mentioned cancer, and there are actually quite a few parallels. So there might be really common cancers that affect a lot of people that are being, uh, subsetted down into different groups depending on the genetics that are related to that particular cancer and therefore what treatments might be most effective. And so I think there's, there's a lot we can each learn from each other between the rare disease and cancer communities. Perhaps as in rare disease we scale up to apply the same strategies to many different rare conditions and patients. Even if they're being tweaked for their particular genetic variant and cancer, sometimes one is subsetting down to treat specifically that, exactly that cancer subtype. So there's a lot we can learn and I completely agree that the, the rare disease community deserves the same chance at at treatments, and the hope that that comes with. Sharon: Thank you. It feels like there needs to be some kind of seismic system change along with this piece around collaboration and how, you know, the science is there, but it's how do we bring it to families who are facing these difficulties with it, you know, their children and, and rare conditions. We'll wrap it up there. Thank you to our guests, Ana Lisa Tavares and Mel Dixon, for joining me as we discussed the evolving landscape of individualised medicines. And thank you for listening. If you'd like to hear more like this, please subscribe on your favorite podcast app. Behind the Genes is produced by Deanna Barac, Florence Cornish, Sophie McLachlan and Patrick Wallace at Bespoken Media.  

After a brief Knight of the Seven Kingdoms chat, Prof. Phil Haberkern discusses the introduction to fan-favorite Lady Olenna. Theme song: Game of Thrones (80's TV Theme) by Highway Superstar Hey there!  Check out https://support.baldmove.com/ to find out how you can gain access to ALL of our premium content, as well as ad-free versions of the podcasts! Join the Club! Join the discussion:  book@baldmove.com  | Discord | Reddit | Forums Leave Us A Review on Apple Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

A question about ASOS derails the Girly Quiz for Dave this week. Can he do what he needs to to win the week?

Sedge Beswick is a public speaker, consultant and trailblazer in the influencer marketing space as the founder of SEEN Connects. Alongside being a hugely successful entrepreneur, Sedge is a passionate advocate for redefining what success, ambition and mental wellbeing looks like for working women.In part one, Sedge shares her journey into social media, behind the scenes running the ASOS social team and what pushed her to launch her own business at 27 years old…Plus, Sedge and Dr Alex George discuss how to best look after yourself when starting a business for the first time.Follow @sedgebeswick and check out her Substack NXT LVL.Order Happy Habits - out now! Follow the podcast on Instagram @thestompcastGet the new, pocket guide version of The Mind Manual nowDownload Mettle: the mental fitness app for men Hosted on Acast. See acast.com/privacy for more information.

Morse code transcription: vvv vvv Single vaccine could protect against all coughs, colds and flus, researchers say Austrian climber found guilty after girlfriend froze to death on mountain Russia Ukraine war How one Russian village lost its fighting age men to conflict Greys Anatomy star Eric Dane dies at 53 after ALS diagnosis Asos co founder dies after Thailand balcony fall Couple trade London home for Carmarthenshire 80 acre nature reserve How much could Andrews arrest hurt the Royal Family UK government finances better than expected in January BBC News weekly quiz Why was the mysterious fossil smiling An unprecedented moment for UK and a former prince

Morse code transcription: vvv vvv Asos co founder dies after Thailand balcony fall An unprecedented moment for UK and a former prince Couple trade London home for Carmarthenshire 80 acre nature reserve Greys Anatomy star Eric Dane dies at 53 after ALS diagnosis BBC News weekly quiz Why was the mysterious fossil smiling Single vaccine could protect against all coughs, colds and flus, researchers say Austrian climber found guilty after girlfriend froze to death on mountain How much could Andrews arrest hurt the Royal Family UK government finances better than expected in January Russia Ukraine war How one Russian village lost its fighting age men to conflict

Morse code transcription: vvv vvv UK government finances better than expected in January BBC News weekly quiz Why was the mysterious fossil smiling Single vaccine could protect against all coughs, colds and flus, researchers say Asos co founder dies after Thailand balcony fall An unprecedented moment for UK and a former prince How much could Andrews arrest hurt the Royal Family Austrian climber found guilty after girlfriend froze to death on mountain Greys Anatomy star Eric Dane dies at 53 after ALS diagnosis Couple trade London home for Carmarthenshire 80 acre nature reserve Russia Ukraine war How one Russian village lost its fighting age men to conflict

Morse code transcription: vvv vvv How much could Andrews arrest hurt the Royal Family Greys Anatomy star Eric Dane dies at 53 after ALS diagnosis Austrian climber found guilty after girlfriend froze to death on mountain An unprecedented moment for UK and a former prince BBC News weekly quiz Why was the mysterious fossil smiling UK government finances better than expected in January Single vaccine could protect against all coughs, colds and flus, researchers say Couple trade London home for Carmarthenshire 80 acre nature reserve Russia Ukraine war How one Russian village lost its fighting age men to conflict Asos co founder dies after Thailand balcony fall

Welcome to Opinions Matter Extra – the totally uncut, completely random bit you normally don't hear before the live show properly kicks off.Jeremy tells the story of being pulled in by the Gardaí with his kids in the car… and the panic that followed, blue lights and all. Adrian, of course, turns it into headlines and takes the absolute piss.There's also a full-on row over “masticating” on mic, Jeremy's buttonless ASOS cardigan (Katie is in stitches), a rant about people tagging dead people on Facebook… and an angry voice note from Vivienne that nearly breaks the internet.

Elise Riley is one of Australia's leading holistic performance experts, renowned for coaching elite athletes including England footballer Ben Chilwell, Dylan Grimes, and Adam Hollioake, as well as hosting the Generation Elevation Podcast.Elise empowers high performers from professional athletes to corporate teams at Google, ASOS, and Soho House to excel in their careers by harnessing the power of breathwork, meditation, and mindfulness to reduce stress, boost energy, and unlock their full potential.Based in London, Elise specialises in helping creatives, performers, and leaders break through mental blocks and step into their power through transformative wellness practices.Elise's InstagramSupport the show

Accenture, American Express, ASOS, EY, Four Seasons Hotels, Google, NBC Universal  are his clientsFrm Royal Air Force Senior Officer, Frm. International Negotiator for the UK Government,  executive coach. Google, Accenture, American Express His first book, 'Find Your Why: A Practical Guide for Discovering Purpose for You and Your Team', co-authored with Simon Sinek and David Mead. Peter gets up every day inspired to enable people to be extraordinary so that they can do extraordinary things. Collaborating with Simon Sinek for over 7 years, he was a founding Igniter and Implementation Specialist on the Start With Why team, teaching leaders and companies how to use the concept of Why."The first step is to distinguish leadership from management. “Management is about handling complexity,” explains Docker, while “leadership is about creating simplicity. It's about cutting through the noise, identifying what's really important, making it personal for people, bringing them together and connecting them.”  ~  Peter Docker in Venteur Magazine January 2023One of Peter's latest books, 'Leading from The Jumpseat: How to Create Extraordinary Opportunities by Handing Over Control'Peter's commercial and industry experience has been at the most senior levels in sectors including oil & gas, construction, mining, pharmaceuticals, banking, television, film, media, manufacturing and services - across more than 90 countries. His career has spanned professional pilot; leading an aviation training and standards organisation; teaching post-graduates at an international college; and running multi-billion dollar procurement projects. A former Royal Air Force senior officer, he has been a Force Commander during combat flying operations and has seen service across the world. He is a seasoned crisis manager, a former international negotiator for the UK Government and executive coach.© 2026 Building Abundant Success!!2026 All Rights ReservedJoin Me on ~ iHeart Media @ https://tinyurl.com/iHeartBASSpot Me on Spotify: https://tinyurl.com/yxuy23bAmazon Music ~ https://tinyurl.com/AmzBASAudacy:  https://tinyurl.com/BASAud

How do you know when it's time to walk away - even from something you've built yourself?Sedge Beswick, consultant, advisor, speaker, and founder, digs deep into what it really takes to make bold career moves, step back as a CEO, and create space for what matters most. If you've ever wondered how to balance ambition with family, deal with overwhelm, and lead with honesty, this episode is for you.We cover: 00:00 – Introduction 01:28 – The courage to change 02:51 – Breaking the “hamster wheel” cycle 05:49 – Building success without a rulebook 07:55 – Childhood confidence and workplace impact 11:31 – The blunt reality of being direct at work 13:38 – Managing people older than you 16:32 – ASOS culture and handling growing pains 18:00 – When opportunity changes your course 19:35 – The power of community for business growth 21:52 – Courage to step down as CEO 22:27 – Mistakes made during maternity leave 23:15 – Hard lessons from deal fatigue 24:43 – Watching someone else lead your business 25:57 – Selling shares and choosing a new path 28:35 – Creating a life with more presence 29:22 – Letting go of identity and titles 32:38 – Pivoting your career with purpose 36:46 – The challenge of saying no and setting boundaries 39:45 – Building a portfolio career and helping others 42:42 – Managing overwhelm and keeping priorities straight 44:01 – Finding headspace as a working parent 45:04 – Do ambition and family ever truly integrate? 48:30 – Advice your future self would give now 50:01 – The power of pausing before big decisionsDon't miss out on this powerful episode on entrepreneurship, business growth, motherhood and more! 

Does Davos hear the voice of a god? If so, is the Faith of the Seven based on a supernatural force within Westeros? How much of Davos's faith is superstitious? Professor Phil Haberkern joins to discuss. Theme song: Game of Thrones (80's TV Theme) by Highway Superstar Hey there!  Check out https://support.baldmove.com/ to find out how you can gain access to ALL of our premium content, as well as ad-free versions of the podcasts! Join the Club! Join the discussion:  book@baldmove.com  | Discord | Reddit | Forums Leave Us A Review on Apple Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

Is there anything that Tyrion can do to earn his father's respect? Was there ever? Joining to discuss: Arthur Amalvy, Pádraig MacCarron, and Iain MacInnis. Theme song: Game of Thrones (80's TV Theme) by Highway Superstar Hey there!  Check out https://support.baldmove.com/ to find out how you can gain access to ALL of our premium content, as well as ad-free versions of the podcasts! Join the Club! Join the discussion:  book@baldmove.com  | Discord | Reddit | Forums Leave Us A Review on Apple Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

Does Arya encounter Nymeria during her escape? If so, why doesn't she recognize her direwolf? Tara Jenkins joins to discuss. Theme song: Game of Thrones (80's TV Theme) by Highway Superstar Hey there!  Check out https://support.baldmove.com/ to find out how you can gain access to ALL of our premium content, as well as ad-free versions of the podcasts! Join the Club! Join the discussion:  book@baldmove.com  | Discord | Reddit | Forums Leave Us A Review on Apple Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome back to the LuxeGen Group Chat – your go-to podcast for pop culture deep dives, TikTok theories and everything we're loving right now. This week, Saroop is joined by Lola and India for a bumper episode covering jungle gossip, social media conspiracies and online nostalgia. The trio dive into this year's ‘I'm A Celeb' line-up (yes, we're obsessed with Aitch and AngryGinge), debate the EsDeeKid x Timothée Chalamet theory, and unpack Ariana Grande and Cynthia Erivo's ‘Wicked: For Good' press tour chaos. Plus, they debate the return of Vine (or should we say… diVine?) and why the internet just isn't ready. In fashion, they're loving the adidas x ASOS satin tracksuit, shearling everything, boat shoes and Palace jackets, as well as the newly revived GAP. For beauty and fragrance, it's all about creamy scents and cosy vibes and in food and drink, the girls share the best spots in London – from The Camberwell Arms to Speedboat Bar – and celebrate the launch of Saroop's new wine and coffee bar in Leeds. Plus, a wholesome moment for David Attenborough's ‘Kingdom', a heated roast potato debate and justice for antelopes everywhere…Follow us on:Instagram | https://bit.ly/3X0xm27TikTok | http://bit.ly/3jvwlBEPodcast | https://open.spotify.com/show/60SxAVVuD3LrgLdlKuy3uH Panel:Saroop Sangha | @saroop.k.s | https://www.instagram.com/saroop.k.s/?hl=en Lola Lawlor | @lolalawlor | https://www.instagram.com/lolalawlor/?hl=enIndia Agyeman | @indiaaagy | https://www.instagram.com/indiaagy/?hl=enAD | Rabanne | https://www.rabanne.com/uk/en_GB/fragrance/p/fame--000000000065170087HOT LISTI'm A Celebrity | https://www.itv.com/imacelebrityStranger Things | https://www.netflix.com/gb/title/80057281THINGS WE'RE LOVINGUrban Outfitters Shearling Trucker Hat | https://tinyurl.com/7e79tmwx H&M Boat Shoes | https://tinyurl.com/yc2bd5xn MKI Miyuki Zoku | https://bit.ly/4opWihb Kingdom | https://www.bbc.co.uk/programmes/m002hdglThe Camberwell Arms | https://thecamberwellarms.co.uk/The Waterman's Arms | https://www.watermansarms.co.uk/Speedboat Bar | https://speedboatbar.co.uk/Vinyl Grounds | https://www.instagram.com/vinyl_grounds/ Hosted on Acast. See acast.com/privacy for more information.

Welcome back to the LuxeGen Group Chat – your go-to podcast for pop culture deep dives, TikTok theories and everything we're loving right now. This week, Saroop is joined by Lola and India for a bumper episode covering jungle gossip, social media conspiracies and online nostalgia. The trio dive into this year's ‘I'm A Celeb' line-up (yes, we're obsessed with Aitch and AngryGinge), debate the EsDeeKid x Timothée Chalamet theory, and unpack Ariana Grande and Cynthia Erivo's ‘Wicked: For Good' press tour chaos. Plus, they debate the return of Vine (or should we say… diVine?) and why the internet just isn't ready. In fashion, they're loving the adidas x ASOS satin tracksuit, shearling everything, boat shoes and Palace jackets, as well as the newly revived GAP. For beauty and fragrance, it's all about creamy scents and cosy vibes and in food and drink, the girls share the best spots in London – from The Camberwell Arms to Speedboat Bar – and celebrate the launch of Saroop's new wine and coffee bar in Leeds. Plus, a wholesome moment for David Attenborough's ‘Kingdom', a heated roast potato debate and justice for antelopes everywhere…Follow us on:Instagram | https://bit.ly/3X0xm27TikTok | http://bit.ly/3jvwlBEPodcast | https://open.spotify.com/show/60SxAVVuD3LrgLdlKuy3uH Panel:Saroop Sangha | @saroop.k.s | https://www.instagram.com/saroop.k.s/?hl=en Lola Lawlor | @lolalawlor | https://www.instagram.com/lolalawlor/?hl=enIndia Agyeman | @indiaaagy | https://www.instagram.com/indiaagy/?hl=enAD | Rabanne | https://www.rabanne.com/uk/en_GB/fragrance/p/fame--000000000065170087HOT LISTI'm A Celebrity | https://www.itv.com/imacelebrityStranger Things | https://www.netflix.com/gb/title/80057281THINGS WE'RE LOVINGUrban Outfitters Shearling Trucker Hat | https://tinyurl.com/7e79tmwx H&M Boat Shoes | https://tinyurl.com/yc2bd5xn MKI Miyuki Zoku | https://bit.ly/4opWihb Kingdom | https://www.bbc.co.uk/programmes/m002hdglThe Camberwell Arms | https://thecamberwellarms.co.uk/The Waterman's Arms | https://www.watermansarms.co.uk/Speedboat Bar | https://speedboatbar.co.uk/Vinyl Grounds | https://www.instagram.com/vinyl_grounds/ Hosted on Acast. See acast.com/privacy for more information.

Was Catelyn's release of the Kingslayer justified? What else could she have done? Phil Haberkern returns to discuss. Theme song: Game of Thrones (80's TV Theme) by Highway Superstar Hey there!  Check out https://support.baldmove.com/ to find out how you can gain access to ALL of our premium content, as well as ad-free versions of the podcasts! Join the Club! Join the discussion:  book@baldmove.com  | Discord | Reddit | Forums Leave Us A Review on Apple Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

In this livestream we welcomed Tanya from A Thousand Eyes and One podcast back to RW! We talk about one of her favorite chapters in ASoIaF - Catelyn VI of ASoS, in which Cat and Robb travel to the Twins for a wedding. Anyone have that uh-oh feeling? Support us on patreon!A Thousand Eyes and One: https://thousandeyespodcast.com/ Hosted on Acast. See acast.com/privacy for more information.

Highlight players for Week 8 using aSOS fantasy funnels. Get 400+ premium podcasts by signing up at www.UTHDynasty.com as a General Manager PLUS subscriber. Also, get access to exclusive shows and deep data dive content from Chad Parsons (and a VIP Chat with the best dynasty owners on the planet) by signing up as an All-Pro at www.Patreon.com/UTH. Thanks for listening, and keep building those dynasties! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Highlight players for Week 7 using aSOS fantasy funnels. Get 400+ premium podcasts by signing up at www.UTHDynasty.com as a General Manager PLUS subscriber. Also, get access to exclusive shows and deep data dive content from Chad Parsons (and a VIP Chat with the best dynasty owners on the planet) by signing up as an All-Pro at www.Patreon.com/UTH. Thanks for listening, and keep building those dynasties! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Highlight players for Week 6 using aSOS fantasy funnels. Get 400+ premium podcasts by signing up at www.UTHDynasty.com as a General Manager PLUS subscriber. Also, get access to exclusive shows and deep data dive content from Chad Parsons (and a VIP Chat with the best dynasty owners on the planet) by signing up as an All-Pro at www.Patreon.com/UTH. Thanks for listening, and keep building those dynasties! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In the third and final installment of our series on Bran Stark, we cover Bran's arc in ASOS and ADWD, as he and his companions journey north to the Wall and its Black Gate, and then continue further north with a mysterious companion to a cave where Bran will begin his apprenticeship with the Three Eyed Crow. Living legends, skinchanging, greenseeing and more! Support us on Patreon Hosted on Acast. See acast.com/privacy for more information.

LG welcomes Scad from Davos Fingers Podcast to chat about one of his favorite chapters in ASOIAF - Arya XIII of ASoS. Vengeance, mercy, Needle, the death of the Hound and MORE! Follow Scad: @davosfingers.bksy.social @beforethelongrest.bsky.social Support us: patreon.com/radiowesteros Hosted on Acast. See acast.com/privacy for more information.